Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk A/S NVO has declared that its GLP ... Lilly’s Next-Generation Triple Agonist GLP-1 Drug Looks Very Promising Lilly has also been working on their next-generation GLP-1 drug ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

If you assume that Lilly and Novo Nordisk continue to dominate the market ... Both of them offer a GLP-1 agonist, so something that mimics basically GLP-1. But the Lilly drugs, Mounjaro and ...

Novo Nordisk is testing a Wegovy follow-up called CagriSema, based on semaglutide and amylin analogue cagrilintide, in phase 3, while Lilly has a triple agonist targeting GLP-1, GIP and glucagon ...

First liraglutide generic cleared for diabetes Finally, the FDA has cleared the first generic of Novo Nordisk's once-daily injectable GLP-1 agonist Victoza (liraglutide), used to treat type 2 ...